HIV vaccine development and broadly neutralizing antibodies
نویسندگان
چکیده
منابع مشابه
HIV vaccine development and broadly neutralizing antibodies
Human immunodeficiency virus-1 (HIV-1) infects about 35 million people worldwide [1]. There is no vaccine in current clinical use. Although available drug treatments are generally effective in controlling infection, they are not curative, can cause significant side effects and are unable to prevent comorbidities such as cardiovascular disease and cancers. In 2012, about 1.6 million people world...
متن کاملDevelopment of an anti-HIV vaccine eliciting broadly neutralizing antibodies
The extreme HIV diversity posts a great challenge on development of an effective anti-HIV vaccine. To solve this problem, it is crucial to discover an appropriate immunogens and strategies that are able to prevent the transmission of the diverse viruses that are circulating in the world. Even though there have been a number of broadly neutralizing anti-HIV antibodies (bNAbs) been discovered in ...
متن کاملBroadly Neutralizing Antibodies for HIV Eradication.
Passive transfer of antibodies has long been considered a potential treatment modality for infectious diseases, including HIV. Early efforts to use antibodies to suppress HIV replication, however, were largely unsuccessful, as the antibodies that were studied neutralized only a relatively narrow spectrum of viral strains and were not very potent. Recent advances have led to the discovery of a l...
متن کاملHIV-1 Envelope gp41 Broadly Neutralizing Antibodies: Hurdles for Vaccine Development
1 Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America, 2 Department of Medicine, Duke University School of Medicine, Durham, North Carolina, United States of America, 3 Department of Pathology, Duke University School of Medicine, Durham, North Carolina, United States of America, 4 Department of Immunology, Duke University School of ...
متن کاملBroadly neutralizing antibodies to prevent HIV-1.
A dvances in technology—especially single-cell antibody cloning techniques—have led to the isolation and characterization of antibodies from people with HIV infection that can neutralize many variants (1). These are referred to as broadly neutralizing antibodies (bnAbs). Such antibodies can be detected in about 25% of persons with untreated HIV-1 infection (2), reflecting a host immune response...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Evolution, Medicine, and Public Health
سال: 2015
ISSN: 2050-6201
DOI: 10.1093/emph/eov004